Bayer Remains Bullish On Asia After Solid Year
This article was originally published in PharmAsia News
Executive Summary
Regional uptake of its innovative medicines drove Bayer to another year of solid growth in the Asia-Pacific region, where the German group sees continued prospects given demographic patterns and unmet needs.